Charles Gaulin, Hematologic Oncologist and Assistant Professor of Medicine at Dartmouth Hitchcock Medical Center and Clinics, shared a post on LinkedIn:
“At ASH25, Anath Lionel presented the results of our retrospective analysis on the impact of extranodal (EN) disease on the clinical outcomes of 522 lymphoma patients treated with CD19-targeted CAR T-cell therapy.
EN disease was associated with a lower complete response rate after CAR T compared to those with only nodal disease or no evidence of disease.
Site-specific analysis revealed that lymphomatous involvement of the liver, peritoneum, or GI tract was significantly associated with lower overall survival in multivariable analysis.
Lower progression-free survival was also observed in patients with liver or peritoneal involvement.
These findings underscore the importance of systematic characterization of EN disease on baseline imaging to inform pre-CAR T risk stratification and potentially guide targeted interventions like bridging RT in high-risk patients.
Read the full abstract here.”
More posts featuring Charles Gaulin.